The immunodeficiency of chronic lymphocytic leukaemia
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Patients with chronic lymphocytic leukaemia (CLL) have progressive immunodeficiency and infection is the commonest cause of death. This review seeks to identify the extent of the abnormality, its cause, clinical significance and any possible remedy. SOURCES OF DATA: TJH has studied CLL for the past 40 years and has scanned or read every paper he could find published on the topic since 1970 and most of those of historical importance published before that date. He has read around the subject, covering relevant articles on immunology, cell biology, oncology and genetics. Furthermore, he has attended most major meetings dealing with CLL in this time and has written many reviews to update the state of knowledge about the topic. He receives weekly updates of papers published on CLL from PubMed and Science Direct with the keywords 'chronic lymphocytic leukaemia'. AREAS OF AGREEMENT: The immunodeficiency chiefly manifests as hypogammaglobulinaemia but involves all elements of the immune system. It is caused by the interpolation of tumour cells among immunological cells and mediated by bi-directional cell contact and secretion of cytokines, which both sustain and invigorate the tumour and suppress immunity. CLL treatment generally makes the immunodeficiency worse. Intravenous immunoglobulin is clinically effective but not cost-effective, while prophylactic antibiotics are useful in appropriate circumstances. Vaccination against infectious disease is usually ineffective. AREAS OF CONTROVERSY: Exactly how the presence of tumour cells in the immune organs renders the patient immunodeficient is controversial as is the clinical significance of minor degrees of immunodeficiency in early or indolent cases. The immunosuppressive effect of most forms of treatment is agreed, but how much this should figure in the choice of treatment is a matter of dispute. GROWING POINTS: The study of tumour-stromal interactions is an area of intense research. AREAS TIMELY FOR DEVELOPING RESEARCH: There has been little done to develop better vaccination strategies in patients with CLL, and although effective antimicrobials have been developed to protect against opportunistic infections, many are both expensive and inconvenient. More work is necessary to define precisely which patients should be offered them and when.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pourgheysari, B., Khan, N., Best, D., Bruton, R., Nayak, L., & Moss, P. A. H. (2007) · Journal of Virology · doi:10.1128/jvi.01262-06 · Cited by 214
Cited by
D’Arena, G., Laurenti, L., Minervini, M. M., Deaglio, S., Bonello, L., De Martino, L., De Padua, L., Savino, L., Tarnani, M., De Feo, V., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2010.08.010 · Cited by 161
“Moreover, evidence is accumulating on the role of T-cells in he pathogenesis and development of CLL [2].”
BackgroundDual effect of oxidative stress on leukemia cancer induction and treatment
Udensi, U. K., & Tchounwou, P. B. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-014-0106-5 · Cited by 135
“infection due to compromised humoral and cellular immunity [127].”
BackgroundMolecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer, L., Egle, A., Hartmann, T. N., & Greil, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.72 · Cited by 125
Hofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P., & Eldering, E. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900321 · Cited by 21
Metadata
- Authors
- Hamblin, A. D., & Hamblin, T. J.
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-01
- Volume
- 87
- Issue
- 1
- Pages
- 49-62
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W2154553633
- Cited by
- 190
- References
- 1
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.